Skip to main content

Joint Infection

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Next Science
Next ScienceAustralia - Sydney
1 program
No-Rinse SolutionN/A1 trial
Active Trials
NCT05519007Recruiting936Est. Dec 2026
Peptilogics
PeptilogicsPA - Pittsburgh
1 program
PLG0206PHASE_11 trial
Active Trials
NCT05137314Completed14Est. Mar 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
PeptilogicsPLG0206
Next ScienceNo-Rinse Solution

Clinical Trials (2)

Total enrollment: 950 patients across 2 trials

NCT05137314PeptilogicsPLG0206

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

Start: Mar 2022Est. completion: Mar 202414 patients
Phase 1Completed
NCT05519007Next ScienceNo-Rinse Solution

Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Start: Sep 2023Est. completion: Dec 2026936 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 950 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.